Prof. Dr. Beat Thürlimann
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Castiglione-Gertsch M, Schmitz S, Thürlimann B, Hürny C. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999; 17:1672-9.
Jun 1, 1999Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
Jun 1, 1999Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999; 17:1672-9
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M F, Morant R, Cavalli F, Castiglione-Gertsch M, Schmitz S F, Thürlimann Beat, Hürny C
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Thürlimann B, Schmitz S, Castiglione-Gertsch M, Hürny C. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). European journal of cancer (Oxford, England : 1990) 1999; 35:913-20.
Jun 1, 1999Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)
Jun 1, 1999European journal of cancer (Oxford, England : 1990) 1999; 35:913-20
Bernhard J, Goldhirsch A, Bonnefoi H, Fey M F, Morant R, Cavalli F, Thürlimann Beat, Schmitz S F, Castiglione-Gertsch M, Hürny C
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
Pagani O, Riva A, Graffeo R, Zimatore M, Zampino G, Bauer J, Borner M, Hess D, Thürlimann B, Buonadonna A, Crivellari D, Martinelli G, Sessa C, Goldhirsch A. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:539-45.
May 1, 1999Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
May 1, 1999Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999; 10:539-45
Pagani O, Riva A, Graffeo R, Zimatore M, Zampino G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Buonadonna A, Crivellari D, Martinelli G, Sessa C, Goldhirsch A
Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients
Sabbioni M, Goldhirsch A, Perey L, Bonnefoi H, Thürlimann B, Bernhard J, Bacchi M, Siegrist H, Hürny C, Castiglione M, Senn H. Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:149-53.
May 1, 1999Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients
May 1, 1999Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:149-53
Sabbioni M E, Goldhirsch A, Perey L, Bonnefoi H, Thürlimann Beat, Bernhard J, Bacchi M, Siegrist H P, Hürny C, Castiglione M, Senn H J
Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial
Köberle D, Bacchus L, Thürlimann B, Senn H. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:21-7.
Jan 1, 1999Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial
Jan 1, 1999Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1999; 7:21-7
Köberle Dieter, Bacchus L, Thürlimann Beat, Senn H J
Hormonal treatment of breast cancer: new developments
Thürlimann B. Hormonal treatment of breast cancer: new developments. Oncology 1998; 55:501-7.
Nov 1, 1998Hormonal treatment of breast cancer: new developments
Nov 1, 1998Oncology 1998; 55:501-7
Thürlimann Beat
Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease
Engler H, Köberle D, Thürlimann B, Senn H, Riesen W. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. Clinical chemistry and laboratory medicine : CCLM / FESCC 1998; 36:879-85.
Nov 1, 1998Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease
Nov 1, 1998Clinical chemistry and laboratory medicine : CCLM / FESCC 1998; 36:879-85
Engler H, Köberle Dieter, Thürlimann Beat, Senn H J, Riesen W F
Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group
Colleoni M, Thürlimann B, Gelber R, Collins J, Lindtner J, Coates A, Goldhirsch A, Castiglione-Gertsch M, Price K, Rudenstam C. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. European journal of cancer (Oxford, England : 1990) 1998; 34:1693-700.
Oct 1, 1998Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group
Oct 1, 1998European journal of cancer (Oxford, England : 1990) 1998; 34:1693-700
Colleoni M, Thürlimann Beat, Gelber R D, Collins J, Lindtner J, Coates A, Goldhirsch A, Castiglione-Gertsch M, Price K, Rudenstam C M
Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG)
Bernhard J, Senn H, Goldhirsch A, Forbes J, Thürlimann B, Marini G, Galligioni E, Gelber R, Castiglione-Gertsch M, Peterson H, Coates A, Hürny C, Rudenstam C. Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG). British journal of cancer 1998; 78:686-93.
Sep 1, 1998Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG)
Sep 1, 1998British journal of cancer 1998; 78:686-93
Bernhard J, Senn H J, Goldhirsch A, Forbes J F, Thürlimann Beat, Marini G, Galligioni E, Gelber R D, Castiglione-Gertsch M, Peterson H F, Coates A S, Hürny C, Rudenstam C M
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI
Pagani O, Price K, Fey M, Simoncini E, Thürlimann B, Cavalli F, Coates A, Crivellari D, Collins J, Lindtner J, Rudenstam C, Goldhirsch A, Gelber R, Castiglione M, O'Neill A, Senn H. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. European journal of cancer (Oxford, England : 1990) 1998; 34:632-40.
Apr 1, 1998Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI
Apr 1, 1998European journal of cancer (Oxford, England : 1990) 1998; 34:632-40
Pagani O, Price K, Fey M, Simoncini E, Thürlimann Beat, Cavalli F, Coates A, Crivellari D, Collins J, Lindtner J, Rudenstam C M, Goldhirsch A, Gelber R D, Castiglione M, O'Neill A, Senn H J
Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer
Lehnert M, Mross K, Schueller J, Thürlimann B, Kroeger N, Kupper H. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. British journal of cancer 1998; 77:1155-63.
Apr 1, 1998Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer
Apr 1, 1998British journal of cancer 1998; 77:1155-63
Lehnert M, Mross K, Schueller J, Thürlimann Beat, Kroeger N, Kupper H
Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials
Hürny C, Van Wegberg B, Bacchi M, Bernhard J, Thürlimann B, Real O, Perey L, Bonnefoi H, Coates A. Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials. British journal of cancer 1998; 77:985-91.
Mar 1, 1998Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials
Mar 1, 1998British journal of cancer 1998; 77:985-91
Hürny C, Van Wegberg B, Bacchi M, Bernhard J, Thürlimann Beat, Real O, Perey L, Bonnefoi H, Coates A
Therapy of Primary Breast Cancer in the 21st Century: A Prediction
Senn, Lampert, Thürlimann B. Therapy of Primary Breast Cancer in the 21st Century: A Prediction. Breast cancer (Tokyo, Japan) 1997; 4:213-220.
Dec 25, 1997Therapy of Primary Breast Cancer in the 21st Century: A Prediction
Dec 25, 1997Breast cancer (Tokyo, Japan) 1997; 4:213-220
Senn, Lampert, Thürlimann Beat
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group
Thürlimann B, Zurlo M, Lanzalone S, di Salle E, Murray R, Roché H, Bonneterre J, Serin D, Paridaens R, Piscitelli G. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. European journal of cancer (Oxford, England : 1990) 1997; 33:1767-73.
Oct 1, 1997Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group
Oct 1, 1997European journal of cancer (Oxford, England : 1990) 1997; 33:1767-73
Thürlimann Beat, Zurlo M G, Lanzalone S, di Salle E, Murray R, Roché H, Bonneterre J, Serin D, Paridaens R, Piscitelli G
Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI
Goldhirsch A, Price K, Pagani O, Fey M, Simoncini E, Cavalli F, Coates A, Crivellari D, Forbes J, Collins J, Lindtner J, Rudenstam C, Thürlimann B, O'Neill A, Castiglione M, Gelber R, Senn H. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997; 8:751-6.
Aug 1, 1997Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI
Aug 1, 1997Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997; 8:751-6
Goldhirsch A, Price K, Pagani O, Fey M F, Simoncini E, Cavalli F, Coates A, Crivellari D, Forbes J, Collins J, Lindtner J, Rudenstam C M, Thürlimann Beat, O'Neill A, Castiglione M, Gelber R D, Senn H J
Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer
Nabholtz J, Murawsky M, Alaki M, Aapro M, Drbal J, Trillet-Lenoir V, Rosso R, Rapoport B, Vandenberg T, Douma J, Deschênes L, Melnychuk D, Bezwoda W, Thürlimann B, Riva A. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. Oncology (Williston Park, N.Y.) 1997; 11:25-30.
Aug 1, 1997Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer
Aug 1, 1997Oncology (Williston Park, N.Y.) 1997; 11:25-30
Nabholtz J M, Murawsky M, Alaki M, Aapro M S, Drbal J, Trillet-Lenoir V, Rosso R, Rapoport B, Vandenberg T A, Douma J, Deschênes L, Melnychuk D, Bezwoda W R, Thürlimann Beat, Riva A
Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)
Thürlimann B, Castiglione M, Hsu-Schmitz S, Cavalli F, Bonnefoi H, Fey M, Morant R, Löhnert T, Goldhirsch A. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). European journal of cancer (Oxford, England : 1990) 1997; 33:1017-24.
Jun 1, 1997Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)
Jun 1, 1997European journal of cancer (Oxford, England : 1990) 1997; 33:1017-24
Thürlimann Beat, Castiglione M, Hsu-Schmitz S F, Cavalli F, Bonnefoi H, Fey M F, Morant R, Löhnert T, Goldhirsch A
Exemestane experience in breast cancer treatment
Lønning P, Paridaens R, Thürlimann B, Piscitelli G, di Salle E. Exemestane experience in breast cancer treatment. The Journal of steroid biochemistry and molecular biology 1997; 61:151-5.
Apr 1, 1997Exemestane experience in breast cancer treatment
Apr 1, 1997The Journal of steroid biochemistry and molecular biology 1997; 61:151-5
Lønning P E, Paridaens R, Thürlimann Beat, Piscitelli G, di Salle E
Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia
Ralston S, Tubiana-Hulin M, Huss H, Hagberg H, Rizzoll R, Lichinitser M, Walls J, Thürlimann B, Steinhauer E, Herrmann Z, Thiébaud D, Body J. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. British journal of cancer 1997; 75:295-300.
Jan 1, 1997Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia
Jan 1, 1997British journal of cancer 1997; 75:295-300
Ralston S H, Tubiana-Hulin M, Huss H J, Hagberg H, Rizzoll R, Lichinitser M R, Walls J, Thürlimann Beat, Steinhauer E U, Herrmann Z, Thiébaud D, Body J J
[Hormone therapy of metastasizing breast carcinoma]
Hagen M, Thürlimann B. [Hormone therapy of metastasizing breast carcinoma]. Therapeutische Umschau. Revue thérapeutique 1996; 53:820-8.
Nov 1, 1996[Hormone therapy of metastasizing breast carcinoma]
Nov 1, 1996Therapeutische Umschau. Revue thérapeutique 1996; 53:820-8
Hagen M F, Thürlimann Beat